Dosage
SILDALIST is a combination product containing Sildenafil and Tadalafil, two PDE5 inhibitors used in the management of erectile dysfunction (ED).
Sildenafil and Tadalafil have different onset and duration profiles, so combination products should only be used with appropriate medical guidance.
| Product Name | SILDALIST |
| Active Ingredients | Sildenafil + Tadalafil |
| Purpose | Erectile Dysfunction (ED) |
| Medicine Class | PDE5 Inhibitors |
| Form | Oral Tablet |
| Manufacturer | RSM Enterprises |
Sildenafil and Tadalafil inhibit phosphodiesterase type 5 (PDE5). This helps support the action of cyclic guanosine monophosphate (cGMP), allowing certain blood vessels to relax and supporting increased blood flow during sexual stimulation.
Note: These medicines generally require sexual stimulation to produce their intended effect.
Sildenafil is generally shorter-acting, while Tadalafil can remain active for a longer period. The exact onset and duration vary between individuals.
Because SILDALIST combines two PDE5 inhibitors, its use should be supervised by a qualified healthcare professional.
Use SILDALIST only according to instructions provided by a qualified healthcare professional or the approved product information.
Do not change the amount, frequency or combination of ED medicines on your own. Taking multiple PDE5 inhibitors together may increase the risk of low blood pressure and other adverse effects.
Food may affect how quickly some ingredients are absorbed. Alcohol can increase dizziness, low blood pressure and other side effects.
Follow professional medical guidance regarding food, alcohol and PDE5-inhibitor medicines.
Speak with a qualified healthcare professional before use if you have:
Possible side effects may include:
Seek urgent medical attention for serious symptoms such as chest pain, fainting, sudden severe vision changes, or an erection that lasts unusually long.
| Medicine / Substance | Why It Matters |
| Nitrate medicines and nitric oxide donors | Can cause a dangerous drop in blood pressure when combined with PDE5 inhibitors. |
| Riociguat and other sGC stimulators | May significantly increase the risk of low blood pressure. |
| Blood-pressure medicines | May increase dizziness or hypotension in some people. |
| CYP3A4 inhibitors or inducers | May alter the concentration of Sildenafil or Tadalafil in the body. |
| Grapefruit products | May affect metabolism of some medicines and potentially increase side effects. |
RSM Enterprises